Search research articles
Contact Us
Filters
Showing results (341-350 of 387) with videos related to
Page
of 39
Sort By:
Gastroenterology
|
September 28, 2023
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
Milan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology
|
September 21, 2023
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B
Ho Soo Chun, George V Papatheodoridis, Minjong Lee, et al.
JHEP Reports : Innovation in Hepatology
|
May 1, 2026
Clinical features and management for CDK4/6 inhibitor-DILI
Mar Riveiro-Barciela, Paula Esteban, Kreina Sharela Vega-Cano, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Hepatology (Baltimore, Md.)
|
February 8, 2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Carlos Fernández Carrillo, Sabela Lens, Elba Llop, et al.
Revista Espanola De Enfermedades Digestivas
|
December 14, 2022
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Joaquín Cabezas, Javier Crespo, Antonio Aguilera, et al.
Journal of Hepatology
|
May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Kosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.
Journal of Virology
|
April 20, 2018
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8<sup>+</sup> T Cells
Hadi Karimzadeh, Muthamia M Kiraithe, Anna D Kosinska, et al.
Journal of Hepatology
|
June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.
Page
of 39
Search research articles
Search
Showing results (341-350 of 387) with videos related to
Sort By:
Page
of 39
Gastroenterology
|
September 28, 2023
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
Milan J Sonneveld, Shao-Ming Chiu, Jun Yong Park, et al.
Journal of Hepatology
|
September 21, 2023
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B
Ho Soo Chun, George V Papatheodoridis, Minjong Lee, et al.
JHEP Reports : Innovation in Hepatology
|
May 1, 2026
Clinical features and management for CDK4/6 inhibitor-DILI
Mar Riveiro-Barciela, Paula Esteban, Kreina Sharela Vega-Cano, et al.
Gastroenterology
|
October 11, 2015
Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, et al.
The Lancet. Gastroenterology & Hepatology
|
August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
Eric Lawitz, Maria Buti, John M Vierling, et al.
Hepatology (Baltimore, Md.)
|
February 8, 2017
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Carlos Fernández Carrillo, Sabela Lens, Elba Llop, et al.
Revista Espanola De Enfermedades Digestivas
|
December 14, 2022
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
Joaquín Cabezas, Javier Crespo, Antonio Aguilera, et al.
Journal of Hepatology
|
May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Kosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.
Journal of Virology
|
April 20, 2018
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8<sup>+</sup> T Cells
Hadi Karimzadeh, Muthamia M Kiraithe, Anna D Kosinska, et al.
Journal of Hepatology
|
June 17, 2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, et al.
Page
of 39